Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $77 from $65 but keeps a Hold rating on the shares after its Q2 earnings beat. The management boosted the product’s guide which also coincided with commentary heard from the competition, even though the company’s Iluvien market access challenges remain and generics performed inline, the analyst tells investors in a research note. Truist adds that the ANI valuation at 10-times EBITDA warrants a neutral stance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Reports Record Growth in Q2 2025
- ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright
- ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler
- Morning Movers: Under Armour sinks following second quarter earnings
- ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42